Alpha 2.0
Login Register
» Authors » Claudia Herrera-De Guise

Claudia Herrera-De Guise

Explore the profile of Claudia Herrera-De Guise including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 42
Followers 0
Related Specialties
Gastroenterology
Social Sciences
Top 10 Co-Authors
Natalia Borruel
Francesc Casellas
Virginia Robles
Zahira Perez Martinez
Luis Fernando Mayorga Ayala
Virginia Robles Alonso
Fernando Gomollon
M Carmen Guillen
Israel Molina
Sandra Agustino Rodriguez
Published In
Rev Esp Enferm Dig
Dig Liver Dis
Nutrients
Heliyon
Gastroenterol Hepatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital
Cespedes Martinez E, Alonso V, Herrera-De Guise C, Mayorga L, Casellas F, Roca-Herrera M, et al.
Rev Esp Enferm Dig . 2023 May; 115(10):567-573. PMID: 37170542
Introduction: immune checkpoint inhibitors (ICI) are increasingly used to treat several types of cancer. These drugs lead to a wide range of toxicities. Immune-related gastrointestinal adverse events are common and...
2.
Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak
Herrera-De Guise C, Mayorga Ayala L, Serra Ruiz X, Alonso V, Sainz N, Ibarz A, et al.
Rev Esp Enferm Dig . 2022 Mar; 115(6):315-319. PMID: 35297257
Background And Aims: Inflammatory bowel disease (IBD) affects many aspects of a patient's life and impairs their health-related quality of life (HRQoL). The COVID-19 outbreak has led to important mobility...
3.
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment
Bastida G, Herrera-De Guise C, Algaba A, Ber Nieto Y, Soares J, Robles V, et al.
Nutrients . 2021 Jun; 13(6). PMID: 34067320
Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial iron (SI)...
4.
Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease
Navarro-Correal E, Borruel N, Robles V, Herrera-De Guise C, Mayorga Ayala L, Perez Martinez Z, et al.
Gastroenterol Hepatol . 2021 Jan; 44(7):481-488. PMID: 33515625
Objective: To report the impact of the COVID-19 pandemic on the activity of nurses working on an inflammatory bowel disease (IBD) unit and to identify reasons for telehealth care and...
5.
asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy
Guillen M, Alcover M, Borruel N, Sulleiro E, Salvador F, Berenguer D, et al.
Heliyon . 2020 May; 6(5):e03940. PMID: 32420499
Background: In recent years anti-TNF therapy has been associated with leishmaniasis in immunocompromised patients from endemic areas. Nevertheless, data on asymptomatic infection in such patients is scarce. The aim of...
6.
Patient preferences for inflammatory bowel disease treatment objectives
Casellas F, Herrera-De Guise C, Robles V, Navarro E, Borruel N
Dig Liver Dis . 2016 Oct; 49(2):152-156. PMID: 27717791
Background: There is currently little evidence about what treatment objectives most interest patients with inflammatory bowel disease (IBD). Aims: To determine patient preferences regarding IBD treatment objectives, specially the attributes...